Last reviewed · How we verify
Cetrorelix acetate and Follitropin alfa
Cetrorelix acetate and Follitropin alfa is a GnRH antagonist and FSH analogue Small molecule drug developed by Merck KGaA, Darmstadt, Germany. It is currently in Phase 2 development for Ovarian stimulation in assisted reproduction. Also known as: Cetrotide, Gonal-f.
Cetrorelix acetate is a GnRH antagonist, and Follitropin alfa is a recombinant human FSH analogue.
Cetrorelix acetate is a GnRH antagonist, and Follitropin alfa is a recombinant human FSH analogue. Used for Ovarian stimulation in assisted reproduction.
At a glance
| Generic name | Cetrorelix acetate and Follitropin alfa |
|---|---|
| Also known as | Cetrotide, Gonal-f |
| Sponsor | Merck KGaA, Darmstadt, Germany |
| Drug class | GnRH antagonist and FSH analogue |
| Target | GnRH receptor and FSH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Cetrorelix acetate works by competitively inhibiting the binding of GnRH to its receptor, thereby reducing the release of gonadotropins. Follitropin alfa stimulates the growth and maturation of follicles in the ovaries, leading to ovulation.
Approved indications
- Ovarian stimulation in assisted reproduction
Common side effects
- Injection site reaction
- Headache
- Nausea
Key clinical trials
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- NATural Ovarian Stimulation (PHASE4)
- Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
- Effectiveness of Low Dose Gonadotropin Stimulation Protocol Vs High Dose Gonadotropin Protocol in Poor Responders (EARLY_PHASE1)
- Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment (PHASE4)
- PErsonalized Addition of Recombinant LH in Ovarian Stimulation (PHASE4)
- Dual Ovarian Stimulation (Duostim) and Shanghai Protocols in Poor Ovarian Responders (PHASE3)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cetrorelix acetate and Follitropin alfa CI brief — competitive landscape report
- Cetrorelix acetate and Follitropin alfa updates RSS · CI watch RSS
- Merck KGaA, Darmstadt, Germany portfolio CI
Frequently asked questions about Cetrorelix acetate and Follitropin alfa
What is Cetrorelix acetate and Follitropin alfa?
How does Cetrorelix acetate and Follitropin alfa work?
What is Cetrorelix acetate and Follitropin alfa used for?
Who makes Cetrorelix acetate and Follitropin alfa?
Is Cetrorelix acetate and Follitropin alfa also known as anything else?
What drug class is Cetrorelix acetate and Follitropin alfa in?
What development phase is Cetrorelix acetate and Follitropin alfa in?
What are the side effects of Cetrorelix acetate and Follitropin alfa?
What does Cetrorelix acetate and Follitropin alfa target?
Related
- Drug class: All GnRH antagonist and FSH analogue drugs
- Target: All drugs targeting GnRH receptor and FSH receptor
- Manufacturer: Merck KGaA, Darmstadt, Germany — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Ovarian stimulation in assisted reproduction
- Also known as: Cetrotide, Gonal-f
- Compare: Cetrorelix acetate and Follitropin alfa vs similar drugs
- Pricing: Cetrorelix acetate and Follitropin alfa cost, discount & access